Tempus Labs (company)

Tempus is an artificial intelligence company developing new treatment plans for patients with cancer by collecting molecular data. The information is then made available to physicians through an operating system that allows doctors to make data-driven treatment decisions with their patients. Tempus was founded by Eric Lefkosky, the co-founder of Groupon, in 2015.

Tempus uses genomic tests to analyze DNA, RNA, and proteomic data to understand a patient's tumor at the molecular level to identify treatment options that are patient-centric. The Tempus platform analyzes thousands of clinical and molecular data points, connecting physicians with up-to-date treatment options and insights for patients based on their molecular profile.

Tempus launched a diagnostic polymerase chain reaction (PCR) test for COVID-19. Tempus' CAP-accredited/CLIA-certified labs in Chicago and Atlanta are supporting the acceleration of testing in the U.S, and expect to test approximately 12,000 patients daily across both labs, with the ability to scale further if needed.

Tempus offers an on-demand virtual case review system that provides clinical support to physicians and care teams in a timely manner. Tempus' Medical Affairs team is available to answer patient report questions in real-time in a secure portal. In addition, Tempus now offers a variety of telehealth support services specific to COVID-19 if needed.

Tempus launched a large research collaboration to structure data for up to 50,000 COVID-19 positive patients. Tempus is partnering with providers to collect data on COVID-19 patients, which Tempus is structuring and de-identifying without cost. In addition, Tempus expects to perform full transcriptomic profiling of approximately 10,000 patients within the cohort. All data will be shared with all participating institutions without restriction.